The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy

The Characteristics of Natural Killer Cells in Chronic Hepatitis B Patients Who Received PEGylated-Interferon versus Entecavir Therapy

Background. To explore the role of natural killer (NK) cells in the process of hepatitis B virus (HBV) clearance and whether their phenotype is related to antiviral treatment outcome in chronic hepatitis B (CHB) patients. Method. We performed a single-center prospective cohort study to analyze chang...

Full description

Bibliographic Details
Main Authors:	Weihua Cao, Minghui Li, Lu Zhang, Yao Lu, Shuling Wu, Ge Shen, Min Chang, Ruyu Liu, Yuanjiao Gao, Hongxiao Hao, Leiping Hu, Wei Yi, Calvin Q. Pan, Yao Xie
Format:	Article
Language:	English
Published:	Hindawi Limited 2021-01-01
Series:	BioMed Research International
Online Access:	http://dx.doi.org/10.1155/2021/2178143

Similar Items

Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir
by: Guei-Ying Chen, et al.
Published: (2015-11-01)

The reduction in CD8+PD-1+ T cells in liver histological tissue is related to Pegylated IFN-α therapy outcomes in chronic hepatitis B patients
by: Ruyu Liu, et al.
Published: (2020-08-01)

Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients
by: Yan L, et al.
Published: (2018-10-01)

Efficacy of telbivudine combined with adefovir dipivoxil and pegylated interferon combined with entecavir as antiviral therapy for chronic hepatitis B: a comparative analysis
by: LI Na, et al.
Published: (2016-09-01)

Efficacy of Pegylated Interferon Monotherapy versus Sequential Therapy of Entecavir and Pegylated Interferon in Hepatitis B e Antigen-Positive Hepatitis B Patients: A Randomized, Multicenter, Phase IIIb Open-Label Study (POTENT Study)
by: Dae Won Jun, et al.
Published: (2018-01-01)

Relationship of T cell immunity and virologic response in patients with chronic hepatitis B receiving pegylated interferon therapy
by: I-Ta Lu, et al.
Published: (2015)

Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy
by: Kanako Yoshida, et al.
Published: (2021-02-01)

Retreatment with Pegylated Interferon Alpha-2a and Ribavirin in Patients with Chronic Hepatitis C Who Have Relapsed or Not Responded to a First Course of Pegylated Interferon-Based Therapy
by: Eric M Yoshida, et al.
Published: (2009-01-01)

Microalbuminuria and pegylated interferon in hepatitis-C patients
by: Yasser Elshahawi, et al.
Published: (2015-01-01)

[Pegylation and interferons in multiple sclerosis]
by: Diego Centonze, et al.
Published: (2016-07-01)

Decrease in regulatory T-cell function in chronic hepatitis C patients receiving pegylated-interferon plus ribavirin
by: Kuo-Chih Tseng, et al.
Published: (2017-05-01)

Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment
by: Ming-Hui Li, et al.
Published: (2017-01-01)

Effect of Pegylated Interferon on Non-Responders and Relapsers with Interferon
by: Hisham O. Akbar, et al.
Published: (2002-04-01)

Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B
by: Zheng C, et al.
Published: (2019-04-01)

Obesity and hepatocellular carcinoma in patients receiving entecavir for chronic hepatitis B
by: Jaemin Lee, et al.
Published: (2016-09-01)

Characteristics of hepatitis C treatment with pegylated interferons and ribavirin
by: Ricardo Jiménez-Méndez, et al.
Published: (2010-01-01)

Pegylated Interferons and Their Use in Clinical Practice
by: Alpay AZAP, et al.
Published: (2003-12-01)

Clinical effect and safety of pegylated interferon-α-2a versus pegylated interferon-α-2b in treatment of chronic hepatitis B
by: JI Weijia
Published: (2019-02-01)

Response predictors to treatment with pegylated interferon in chronic hepatitis B
by: Paulo Roberto Abrão Ferreira, et al.

Response predictors to treatment with pegylated interferon in chronic hepatitis B
by: Paulo Roberto Abrão Ferreira, et al.
Published: (2010-09-01)

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin
by: Roberto J Carvalho-Filho, et al.
Published: (2010-03-01)

Individualized treatment with pegylated interferon-α for chronic hepatitis B
by: WAN Mobin
Published: (2018-05-01)

Pegylated interferon, but not conventional interferon therapy induced severe skin lesions
by: Zhengxiao Li, et al.
Published: (2012-07-01)

Pegylated Interferon (Alone or With Ribavirin) for Chronic Hepatitis C in Haemodialysis Population
by: Mario Espinosa, et al.
Published: (2015-05-01)

Pegylated interferon-alfa plus ribavirin therapies for chronic hepatitis C
by: T Kanda, et al.
Published: (2011-03-01)

Efficacy of early treatment of acute hepatitis C infection with pegylated interferon
by: N. Amina
Published: (2014-04-01)

Conventional Versus Pegylated Interferons in Treatment of HCV Patients
by: M Amirbigi, et al.
Published: (2012-04-01)

[Pegylated interferon beta-1a on the Italian market]
by: Mario Eandi
Published: (2016-07-01)

Effect of entecavir antiviral therapy alone or combined with interferon on the risk of hepatocellular carcinoma in patients with chronic hepatitis B
by: SUN Jing
Published: (2020-09-01)

The Efficacy and Safety of Entecavir and Interferon Combination Therapy for Chronic Hepatitis B Virus Infection: A Meta-Analysis.
by: Qiao-Ling Xie, et al.
Published: (2015-01-01)

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation
by: J Shepherd, et al.
Published: (2007-03-01)

Effect of pegylated interferon α-2a combined with thymosin α1 on quality of life in patients with chronic hepatitis B
by: LU Jianguo
Published: (2013-12-01)

Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
by: Ming-Lun Yeh, et al.
Published: (2015-01-01)

Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3
by: Aline Gonzalez Vigani, et al.
Published: (2012-05-01)

Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3
by: Aline Gonzalez Vigani, et al.

A case of autoimmune hepatitis following pegylated interferon treatment of chronic hepatitis delta
by: Feruze Enc, et al.
Published: (2020-08-01)

Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon‐α in Woodchucks Chronically Infected With Woodchuck Hepatitis Virus
by: Stephan Menne, et al.
Published: (2020-06-01)

A study of compliance in patients with HBeAg-negative chronic hepatitis B receiving entecavir treatment
by: TAO Junxiu, et al.
Published: (2017-08-01)

Can pegylated interferon improve the outcome of polycythemia vera patients?
by: Elena Crisà, et al.
Published: (2017-01-01)

Organizing Pneumonia Associated with Pegylated Interferon α and Ribavirin Therapy
by: Amit Chopra, et al.
Published: (2015-01-01)